Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Rationale And Objectives: Accurate risk stratification in human epidermal growth factor receptor 2-positive surgically resectable advanced gastric cancer (HER2-p SRAGC) can strengthen monitoring for high-risk patients, allowing timely HER2-specific treatment and potentially improving prognosis. Therefore, we aimed to develop a CT radiomics model for predicting outcomes in HER2-p SRAGC and compare it with the 8th edition TNM staging system.
Materials And Methods: 621 HER2-p SRAGC patients who received either radical gastrectomy or radical gastrectomy after neoadjuvant therapy or chemotherapy were retrospectively enrolled in two hospitals and assigned to a training (n=330), an internal validation (n=143) and an external validation (n=148) cohorts. A radiomics model incorporating Radscore and clinical scores was constructed. Model performance was assessed by Kaplan-Meier estimator, Log-rank test, and Harrell's C-index.
Results: The radiomics model was correlated with the overall survival (OS) across all cohorts, with C-indexes of 0.711[95% confidence interval (CI): 0.666-0.756; p<0.001; training], 0.669 (95%CI: 0.585-0.753; p=0.009; internal validation) and 0.693 (95%CI: 0.597-0.789; p=0.015; external validation). In all study cohorts, the radiomics model successfully stratified patients into high-risk and low-risk groups, and outweighed individual scores, pathological staging (pTNM), and clinical staging (cTNM) but was inferior to post-neoadjuvant therapy staging (ypTNM). Additionally, the radiomics model had added value to the prognostic efficacy of pTNM and was unaffected by patient age and gender.
Conclusion: The radiomics model delivers individualized prognosis prediction of HER2-p SRAGC, surpassing clinical scores, and both pTNM and cTNM in forecasting OS. It confers incremental benefit to pTNM and exhibits certain universality across patient types.
Trial Registration: Retrospectively registered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acra.2025.05.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study.
Acad Radiol
September 2025
Department of Radiology, The First Affiliated Hospital of Zhengzhou University, No. 1, East Jianshe Road, Zhengzhou 450052, Henan Province, China (J.G., L.L., P.L.); Henan Key Laboratory of Image Diagnosis and Treatment for Digestive System Tumor & Henan International Joint Laboratory of Medical Ima
Rationale And Objectives: Accurate risk stratification in human epidermal growth factor receptor 2-positive surgically resectable advanced gastric cancer (HER2-p SRAGC) can strengthen monitoring for high-risk patients, allowing timely HER2-specific treatment and potentially improving prognosis. Therefore, we aimed to develop a CT radiomics model for predicting outcomes in HER2-p SRAGC and compare it with the 8th edition TNM staging system.
Materials And Methods: 621 HER2-p SRAGC patients who received either radical gastrectomy or radical gastrectomy after neoadjuvant therapy or chemotherapy were retrospectively enrolled in two hospitals and assigned to a training (n=330), an internal validation (n=143) and an external validation (n=148) cohorts.